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Abstract
Background: Elevated Hsp90 expression has been documented in breast ductal carcinomas, whereas decreased
Hsp90 expression has been reported in precursor lobular lesions. This study aims to assess Hsp90 expression in
infiltrative lobular carcinomas of the breast.
Methods: Tissue specimens were taken from 32 patients with infiltrative lobular carcinoma. Immunohistochemical
assessment of Hsp90 was performed both in the lesion and the adjacent normal breast ducts and lobules; the
latter serving as control. Concerning Hsp90 assessment: i) the percentage of positive cells and ii) the intensity were
separately analyzed. Subsequently, the Allred score was adopted and calculated. The intensity was treated as an
ordinal variable-score (0: negative, low: 1, moderate: 2, high: 3). Statistical analysis followed.
Results: All infiltrative lobular carcinoma foci mainly presented with a positive cytoplasmic immunoreaction for
Hsp90. Compared to the adjacent normal ducts and lobules, infiltrative lobular carcinoma exhibited a statistically
significant decrease in Hsp90 expression, both in terms of Hsp90 positive cells (%) and Allred score (74.2 ± 11.2 vs.
59.1 ± 14.2 p = 0.0001; 7.00 ± 0.95 vs. 6.22 ± 1.01, p = 0.007, Wilcoxon matched-pairs signed-ranks test).
Concerning the intensity of Hsp90 immunostaining only a marginal decrease was noted (2.16 ± 0.68 vs. 1.84 ±
0.63, p = 0.087, Wilcoxon matched-pairs signed-ranks test).
Conclusion: ILC lesions seem to exhibit decreased Hsp90 expression, a finding contrary to what might have been
expected, given that high Hsp90 expression is a trait of invasive ductal carcinomas.
Background
Hsp90 is an abundant protein in mammalian cells [1]. It
forms several discrete complexes, each containing dis-
tinct groups of cochaperones that assist protein folding
and refolding during stress, protein transport and degra-
dation [2]. Hsp90 interacts with a variety of proteins that
play key roles in breast neoplasia; including estrogen
receptors (ER), tumor suppressor p53 protein, angiogen-
esis transcription factor HIF-1alpha, antiapoptotic kinase
Akt, Raf-1 MAP kinase and a variety of receptor tyrosine
kinases, such as erbB2 (reviewed in [3]).
Elevated Hsp90 expression has been documented in
breast ductal carcinomas [4-6] as contributing to the
proliferative activity of breast cancer cells. Hsp90 over-
expression has been proposed as a mechanism through
which breast cancer cells become resistant to various
stress stimuli [6]. In this context, higher Hsp90 expres-
sion may represent a marker of poor prognosis [7].
Given the above, it would appear that pharmacological
inhibition of Hsps can provide therapeutic opportunities
in the field of cancer treatment [8-12]; 17- allylamino,
17-demethoxygeldanamycin (17-AAG), the first Hsp90
inhibitor to undergo clinical development, has yielded
promising results [3,13]. As the above demonstrates, a
wide variety of studies on Hsp90 expression in breast
cancer have emerged; nevertheless, there is a marked
scarcity of data on Hsp90 expression in lobular neo-
plasia/infiltrative lobular carcinomas in particular.
Contrary to what might have been expected, our pre-
vious work in lobular neoplasia (LN) has demonstrated
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any medium, provided the original work is properly cited.downregulation of Hsp90, in respect to both the level of
Hsp90 intensity and Allred score [14]. According to
the most recent WHO classification, LN includes the
designations atypical lobular hyperplasia (ALH) and
lobular carcinoma in situ (LCIS) and refers to the
entire spectrum of atypical epithelial proliferation ori-
ginating in the terminal ductlobular unit, with or with-
out involvement of ducts [15]. Nowadays, it is widely
known that LN represents a risk factor and a non-obli-
gatory precursor for the subsequent development of
invasive carcinoma in either breast, of either ductal or
lobular type [16].
This study aims to go beyond LN, assessing Hsp90
expression in infiltrative lobular carcinomas (ILC). The
examination of ILC lesions may subsequently prove to
have significant implications for the viability of Hsp90
inhibitors in breast lobular lesions.
Methods
This study involved formalin-fixed, paraffin-embedded
tissue specimens from 32 patients with ILC. The
patients’ age at operation ranged between 35 and 74
(median age: 53 years); information regarding the
patients’ clinicopathological features was also retrieved.
The diagnosis of ILC was established by vacuum-
assisted breast biopsy, excisional breast biopsy, lumpect-
omy and modified radical mastectomy. Cases of ILC
coexisting with atypical ductal hyperplasia, ductal carci-
noma in situ, or invasive ductal carcinoma were
excluded.
Hsp90 was immunohistochemically detected using the
mouse monoclonal antibody Hsp90 (clone JPB24, NCL-
Hsp90, Novocastra supplied by Menarini). The dilution
was 1:500 and the incubation time was 18 h (at 4°C).
The visualization was performed using the Dako Envi-
sion kit. Antigen retrieval was achieved in 0.01 M citrate
buffer (pH = 6.0) at 85°C for 15 min. Immunohisto-
chemical assessment of Hsp90 was performed both in
the lesion and the adjacent normal breast ducts and
lobules, the latter serving as control. Negative controls
were assessed by omitting the primary antibody.
Concerning Hsp90 assessment: i) the percentage of
positive cells and ii) the intensity were separately ana-
lyzed. Subsequently, the Allred score was appropriately
calculated (Table 1) [17,18].
For immunohistochemistry (IHC), the following anti-
bodies were used: PgR (636, Dako), ER (ID5, Dako)
and c-erbB-2 (CB11, Novocastra™). Sections (4 μm
thick) cut from formalin-fixed paraffin embedded tis-
sue were used. After deparaffinization in xylene and
hydration in graded ethanol solutions, the sections of
breast carcinoma tissue were subjected to pretreatment
in order to enhance antigen retrieval. The EnVision +
System-HRP (DAB) (DakoCytomation, Glostrup,
Danemark) was used with primary antibodies against
the following antigens: PgR, ER and c-erbB-2. Immu-
nohistochemistry was performed according to the pro-
tocols provided by the manufacturer. Concerning the
immunohistochemical expression of ER and PR, both
the intensity (negative, 1+ to 3+) and percentage of
immunopositive cells were evaluated. Subsequently, the
Allred score was calculated [16].
The expression of c-erbB-2 was assessed as follows: i)
negative, when no staining was documented or when
membrane staining was present in less than 10% of
tumor cells, ii) weak staining (+), when partial mem-
brane staining was documented in more than 10% of
tumor cells, iii) moderate staining (++) when weak/mod-
erate complete membrane staining was present in more
than 10% of tumor cells and iv) strong staining when
strong, complete membrane staining was observed in
more than 10% of tumor cells. Cases with negative and
weak c-erbB2 staining were considered as negative,
whereas cases with strong c-erbB2 staining were consid-
ered as positive. In cases with moderate staining, CISH
was performed; subsequently these cases were consid-
ered as negative or positive.
In all cases, ten fields (×40 magnification) were
assessed and a minimum of 100 cells were evaluated in
the designated areas, so as to appraise the lesion as a
whole. The immunohistochemical evaluation was per-
formed independently by two consultant histopatholo-
gists (AN and AL).
Kappa statistic was performed to assess inter-rater
agreement at both the estimation of Hsp90 percentage
and intensity; for the optimal interpretation of the
result, it should be kept in mind that pathologists rated
Hsp90 percentage at an increment of 5% i.e., possible
values are: 60%, 65%, 70% and so forth.
The intensity was treated as an ordinal variable-score
(0: negative, low: 1, moderate: 2, high: 3). Regarding
Allred score and Ki-67 percentage, all numbers are pro-
vided as mean ± SD. Two main analyses were per-
formed: i. comparison of Hsp90 Allred score between
the lesion and the adjacent normal ducts and lobules
and ii. evaluation of the associations between Hsp90
Allred score and ER positivity, progesterone receptor
(PR) positivity, c-erbB2 status and Ki-67 (%). Due to
deviation from the normal distribution, non-parametric
statistics were chosen. The statistic performed in each
case is mentioned in parentheses in the text. Where
appropriate, power calculations are presented. Statistical
analysis was performed with STATA 8.0 statistical soft-
ware (Stata Corporation, College Station, TX, USA).
Informed consent was obtained from all participants
in this study. This study has been approved by the local
Ethics Committee, in accordance with the Helsinki
Declaration.
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The description of the study sample is presented in
Table 2. Hsp90 exhibited mainly cytoplasmic immunor-
eactivity in epithelial cells of normal breast (ducts and
lobules) (Figure 1), and ILC (Figure 2). Some epithelial
cells of ILC also showed nuclear staining; nevertheless,
all ILC foci mainly presented with a positive cytoplasmic
immunoreaction for Hsp90. The positive cell percentage
and the staining intensity were evaluated.
The percentage of Hsp90 positive cells, the intensity of
Hsp90 staining, as well as the Allred score are presented
in detail in Table 3 and Table 4. Concerning ILC, the
inter-observer agreement was 90.6% for Hsp90 intensity
(kappa = 0.8289, p < 0.0001, rejecting the null hypoth-
esis of random ratings) and 81.3% for Hsp90 percentage
(kappa = 0.7780, p < 0.0001, rejecting the null hypoth-
esis of random ratings).
A statistically significant decrease in Hsp90 expression,
both in terms of positive cells(%) and Allred score, was
noted (74.2 ± 11.2 vs. 59.1 ± 14.2 p = 0.0001; 7.00 ± 0.95
vs. 6.22 ± 1.01, p = 0.007, Wilcoxon matched-pairs signed-
ranks test). The decrease in Hsp90 intensity (2.16 ± 0.68
vs. 1.84 ± 0.63) was of borderline statistical significance
(p = 0.087, Wilcoxon matched-pairs signed-ranks test).
Null association was noted between Hsp90 Allred score
and ER positivity (6.40 ± 0.55 for ER negative cases vs.
6.19 ± 1.08 for ER positive cases, p = 0.547, Mann-Whit-
ney-Wilcoxon test for independent samples), PR positiv-
ity (6.43 ± 0.98 for PR negative cases vs. 6.16 ± 1.03 for
PR positive cases, p = 0.532, same test), c-erbB2 status
(6.20 ± 1.04 for c-erbB2 negative cases vs. 6.29 ± 0.95 for
c-erbB2 positive cases, p = 0.904, same test) as well as
Ki-67(%) (Spearman’s rho = -0.083, p = 0.651).
Discussion
To our knowledge, this is the first study to demonstrate
a significantly decreased Hsp90 expression in infiltrative
lobular carcinomas, both in terms of percentage and
Allred score. This finding could be viewed in a wider
context; the present findings are consistent with those
previously described by our team on precursor lobular
lesions (LN).
The persistent downregulation of Hsp90 expression
throughout the whole lobular series (at the precursor
a n di n v a s i v ec o m p o n e n t s )m a yb ec o n t r a r yt ow h a t
might have been expected; it is known that Hsp90 over-
expression is a feature of invasive ductal carcinomas
[5-7]. It is thus tempting to speculate that the whole
lobular series may display a discrete, less intense profile
of Hsp90 expression, which differentiates itself from the
marked upregulation in ductal carcinomas.
The underlying mechanisms of this discrepancy
remain elusive. ILC express c-erbB2 at a far less extent
than ductal carcinomas [19]. Given that c-erbB2 has
Table 1 Algorithm for the calculation of the Allred score
[17,18]
Observed values “Allocated” values for the calculation
of the 0-8 Allred score
Percentage of positive cells
None 0
<1% 1
1% to 10% 2
10% to 33.3% 3
33.3% to66.7% 4
more than 66.7% 5
Intensity of staining
weak 1
intermediate 2
strong 3
Table 2 Characteristics of patients and histological
features of invasive lobular carcinomas.
Categorical Variables Frequency (%)
Menopausal status
Premenopausal 8 (25.0)
Postmenopausal 24 (75.0)
First-degree relative with breast cancer
Yes 6 (18.8)
No 26 (81.2)
Breastfeeding
Yes 24 (75.0)
No 8 (25.0)
Grade
1 5 (15.6)
2-3 27 (84.4)
Tumor diameter
<2 cm 6 (18.8)
≥2 cm 26 (81.2)
Nodal status
Positive 8 (25.0)
Negative 24 (75.0)
Metastasis
Yes 0 (0.0)
No 32 (100.0)
ER status
Positive 27 (84.4)
Negative 5 (15.6)
PR status
Positive 25 (78.1)
Negative 7 (21.9)
c-erbB2 status
Positive 7 (21.9)
Negative 25 (78.1)
Continuous variable mean ± SD
Ki-67 (%) 12.0 ± 5.1
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Figure 2 Infiltrative lobular carcinoma with slight Hsp90 immunoreactivity (×200) (Figure 2a, 2b, 2c) and with moderate Hsp90
expression (×200) (Figure 2d).
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expression [7], it is tempting to speculate that downre-
gulation of Hsp90 in ILC may be a c-erbB2 related
event. However, no significant association was noted
between c-erbB2 status and Hsp90 Allred score in our
cohort; this null, inconclusive finding should be inter-
preted with caution, as only seven cases were c-erbB2
positive. In other words, the small number of c-erbB2
positive cases may have blurred the association between
c-erbB2 and Hsp90 at a certain extent.
The present study comes to expand the results of our
previous immunohistochemical study on LN lesions. In
the case of LN we have postulated that the decreased
Hsp90 expression may be partly due to the self-limiting,
close-to-normal character of the lesion, as well as to the
relatively milder stress response when compared to can-
cer [14]. The present study uncovers an Hsp90 expres-
sion pattern (relative decrease) which seems applicable
to the whole continuum of lobular lesions and may be
thus revealing of an inherent trend of the whole breast
lobular series. Nevertheless, the fact that the finding
seems to persist in the invasive lesions may suggest that
the proliferation advantage in lobular lesions is an
Hsp90-independent process. This hypothesis seems
further supported by the fact that Ki-67 expression was
not associated with Hsp90 expression in infiltrative lob-
ular carcinomas.
The downregulation of Hsp90 for the entire lobular
series is a phenomenon which may be of particular clin-
ical significance. Anti-Hsp90 drugs are currently tested
in trials with very promising results [20-23]. Neverthe-
less, no trials have focused on lobular lesions. Conse-
quently, it would appear that the effects of Hsp90
targeting drugs should be evaluated separately on ductal
and lobular carcinomas, since the effectiveness may be
limited accordingly.
In our cases, some epithelial cells of ILC showed
scarce (i.e. <5%) nuclear Hsp90 localization; it should be
noted that the aforementioned nuclear staining was not
taken into account at the calculation of Allred score, as
such a percentage may have been caused by technical
reasons. Allred score was based exclusively on cytoplas-
mic Hsp90 staining. Nevertheless, the significance of
nuclear Hsp90 expression remains elusive, as some stu-
dies have not documented any nuclear Hsp90 expres-
sion in invasive ductal carcinomas [7], as opposed to
other studies [24]. This finding has already been
reported in invasive breast carcinomas and has been
correlated with MHC class I expression [25].
In relation to the limitations of this study, it is worth
referring to a number of points. Firstly, the small study
sample should be declared; as a result, the present find-
ings need to be reproduced in larger follow-up studies,
so as to thoroughly examine the robustness as well as
the clinical and prognostic implications of this immuno-
histochemical study. Accordingly, the fact that the
decrease in Hsp90 intensity was solely of borderline sta-
tistical significance may not denote an inconsistency in
results, as it could reach formal statistical significance in
t h ec o n t e x to fal a r g e rs a m p l es i z e( l a r g e rc o h o r t ) .I n
any event, the Allred score, integrating both percentage
and intensity, confirmed the decrease despite the rela-
tively small sample size.
Another limitation of this study pertains to the
method performed (i.e. immunohistochemistry). Not-
withstanding, Hsp90 downregulation might not be con-
testable given its clear demonstration in a relatively less
sensitive assessment (immunohistochemical procedure
and visual scoring). To ensure the objectivity of the
assessment, the percentage and intensity were assigned
by two independent pathologists blind to one another’s
results. Nevertheless, under the light of the above inher-
ent limitations of the method adopted, the results need
to be confirmed by other methods apart from immuno-
histrochemistry (such as Western blot). Indeed, in vitro
mechanistic studies seem indispensable for definitive
conclusions; it should be acknowledged that such
mechanistic studies were not feasible in the clinical
Table 3 Expression of Hsp90 in invasive lobular carcinomas (ILC) and the normal adjacent ducts and lobules (mean ±
SD)
Adjacent normal ducts and lobules ILC p
a
Hsp90 intensity (score) 2.16 ± 0.68 1.84 ± 0.63 0.087
Hsp90 positive cells (%) 74.2 ± 11.2 59.1 ± 14.2 0.0001
Hsp90 Allred score 7.00 ± 0.95 6.22 ± 1.01 0.007
ap-value derived from Wilcoxon matched-pairs signed-ranks test
Table 4 Detailed results of Allred score in invasive
lobular carcinomas (ILC) and the normal adjacent ducts
and lobules
Allred score Adjacent normal ducts and lobules ILC
4 0 (0.0) 1 (3.1)
5 4 (12.5) 6 (18.8)
6 2 (6.2) 14 (43.7)
7 16 (50.0) 7 (21.9)
8 10 (31.3) 4 (12.5)
Figures are frequency (percentage).
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efforts overcoming such limitations seem to be needed
for further substantiation of the present findings in the
future.
Conclusion
In conclusion, it can be said that Hsp90 expression
seems decreased in ILC lesions compared to the normal
adjacent breast ducts and lobules, a finding contrary to
what might have been expected, given that high Hsp90
expression is a trait of invasive ductal carcinomas.
Further studies adopting quantitative procedures, asses-
sing mRNA levels and the pathophysiologically asso-
ciated estrogen receptor status seem mandatory.
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